Table 2.
Clinical Characteristics of SSc Patients Studied
| Sample | Age | Sex | Disease duration (years) | SSc subset |
|---|---|---|---|---|
| Skin tissue immunostaining | ||||
| SSc1 | 59 | F | 0.40 | dcSSc |
| SSc2 | 44 | F | 1.80 | dcSSc |
| SSc3 | 21 | F | 6.00 | dcSSc |
| SSc4 | 42 | F | 0.58 | dcSSc |
| SSc5 | 44 | F | 0.40 | lcSSc |
| SSc6 | 49 | F | 2.00 | lcSSc |
| SSc7 | 54 | M | 3.00 | dcSSc |
| SSc8 | 64 | M | 0.17 | dcSSc |
| SSc9 | 30 | F | 2.5 | dcSSc |
| SSc10 | 24 | F | 9.00 | dcSSc |
| SSc11 | 73 | F | 0.20 | dcSSc |
| SSc12 | 43 | F | 10.00 | dcSSc |
| SSc13 | 31 | F | 15.00 | lcSSc |
| SSc14 | 57 | F | 10.00 | dcSSc |
| SSc15 | 54 | F | 12.00 | dcSSc |
| SSc16 | 25 | F | 1.00 | dcSSc |
| SSc17 | 16 | F | 7.00 | dcSSc |
| SSc18 | 55 | F | 0.30 | lcSSc |
| SSc19 | 67 | M | 0.25 | dcSSc |
| SSc20 | 57 | F | 3.00 | dcSSc |
| SSc21 | 30 | F | 2.50 | dcSSc |
| SSc22 | 43 | M | 0.08 | dcSSc |
| SSc23 | 63 | F | 0.90 | lcSSc |
| Lung tissue immunostaining | ||||
| SSc25 | 57 | M | N/A | dcSSc |
| SSc29 | 60 | F | N/A | dcSSc |
| SSc30 | 58 | F | N/A | lcSSc |
| SSc31 | 35 | M | N/A | SSc sine scleroderma |
| Explanted skin fibroblasts | ||||
| S10 | 36 | F | 0.91 | lcSSc |
| S11 | 46 | F | 1.00 | dcSSc |
| S12 | 54 | M | 1.00 | dcSSc |
| S34 | 38 | F | 1.00 | dcSSc |
| SU9 | N/A | N/A | <5.00 | dcSSc |
lcSSc, limited cutaneous SSc; dcSSc, diffuse cutaneous SSc.